Harvard Bioscience, Inc. (HBIO)
- Previous Close
3.4400 - Open
3.4600 - Bid 3.3600 x 100
- Ask 3.4200 x 100
- Day's Range
3.3500 - 3.4600 - 52 Week Range
3.3300 - 6.2000 - Volume
55,429 - Avg. Volume
91,331 - Market Cap (intraday)
146.358M - Beta (5Y Monthly) 1.46
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2000 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.92
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
www.harvardbioscience.comRecent News: HBIO
Performance Overview: HBIO
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HBIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HBIO
Valuation Measures
Market Cap
146.36M
Enterprise Value
183.47M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.35
Price/Book (mrq)
2.13
Enterprise Value/Revenue
1.72
Enterprise Value/EBITDA
84.20
Financial Highlights
Profitability and Income Statement
Profit Margin
-8.18%
Return on Assets (ttm)
-0.69%
Return on Equity (ttm)
-12.20%
Revenue (ttm)
106.79M
Net Income Avi to Common (ttm)
-8.73M
Diluted EPS (ttm)
-0.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
4.25M
Total Debt/Equity (mrq)
60.11%
Levered Free Cash Flow (ttm)
13.77M
Research Analysis: HBIO
Company Insights: HBIO
HBIO does not have Company Insights